Sumitomo Pharma Co., Ltd. (formerly Sumitomo Dainippon Pharma) is a Japanese pharmaceutical company headquartered in Osaka, Japan, with a focus on psychiatry, neurology, oncology, and regenerative medicine. The company was formed through the merger of Sumitomo Pharmaceuticals (1913) and Dainippon Sumitomo Pharma (1897).
Overview
...Sumitomo Pharma Co., Ltd. (formerly Sumitomo Dainippon Pharma) is a Japanese pharmaceutical company headquartered in Osaka, Japan, with a focus on psychiatry, neurology, oncology, and regenerative medicine. The company was formed through the merger of Sumitomo Pharmaceuticals (1913) and Dainippon Sumitomo Pharma (1897).
Overview
Mermaid diagram (expand to render)
Sumitomo Pharma has evolved into a major Japanese pharmaceutical company with a strong focus on central nervous system disorders and innovative cell therapy programs. The company became Sumitomo Pharma in 2019 following brand unification["@corporate"].
Funding
- IPO: 2005 (TSE: 4506)
- Market Cap: ~$5B (2026)
Corporate Highlights
- Founded: 1913 (Sumitomo Pharmaceuticals)
- Headquarters: Osaka, Japan
- Employees: Approximately 7,000
- TSE: 4506
History and Development
Origins (1897-2005)
The company traces its roots to two major pharmaceutical companies:
- Dainippon Sumitomo Pharma: Founded in 1897 as Dainippon Pharmaceutical Co.
- Sumitomo Pharmaceuticals: Founded in 1913
Merger (2005)
In 2005, Sumitomo Pharmaceuticals and Dainippon Sumitomo Pharma merged to form Sumitomo Dainippon Pharma, creating one of Japan's largest pharmaceutical companies.
Brand Unification (2019)
The company rebranded to Sumitomo Pharma in 2019 to unify its global identity.
Key Programs
Regenerative Medicine / Cell Therapy
CTI-ND1601: iPSC-derived dopaminergic neuron progenitor cells for Parkinson's disease[@ctind]
- Mechanism: Transplantation of dopamine-producing neurons derived from induced pluripotent stem cells (iPSCs)
- Stage: Phase 1/2 clinical trials in Japan
- Significance: Potentially disease-modifying treatment for Parkinson's disease
- Partner: CiRA (Kyoto University)
The cell therapy approach aims to replace lost dopamine-producing neurons in the substantia nigra, addressing the root cause of Parkinson's disease rather than just managing symptoms.
CNS Pipeline
| Drug Candidate | Indication | Mechanism | Stage |
|---------------|------------|-----------|-------|
| SEP-363856 (Ultracelest) | Schizophrenia | TAAR1/5-HT1A agonist | Approved in Japan |
| DSP-5336 | Amyotrophic lateral sclerosis | RNA splicing modulator | Phase 1/2 |
| DSP-2230 | Neuropathic pain | Sodium channel blocker | Phase 1 |
| SEP-539190 | Parkinson's disease | Novel mechanism | Phase 1 |
Neurological Relevance
Sumitomo's neuroscience pipeline addresses major neurodegenerative and psychiatric disorders[@neuroscience]:
Parkinson's Disease Cell Therapy
CTI-ND1601 represents one of the most advanced cell therapy approaches for Parkinson's disease:
- iPSC-derived dopamine neurons can replace lost endogenous neurons
- Potential for disease modification rather than symptom control
- Addresses motor symptoms through physiological dopamine replacement
- May slow or halt disease progression
- Phase 1/2 trials ongoing in Japan[@ipsc]
Novel Schizophrenia Treatment
SEP-363856 (Ultracelest) represents a new mechanism for schizophrenia[@sep]:
- Target: Trace amine-associated receptor 1 (TAAR1) and 5-HT1A
- Difference: Does not directly block dopamine D2 receptors
- Benefits: May improve cognitive and negative symptoms
- Approval: Japan (2024)
ALS RNA Therapy
DSP-5336 targets RNA splicing in ALS:
- Modifies SOD1 gene expression
- Potential for personalized medicine approaches
- Addresses genetic forms of ALS
Neuropathic Pain
DSP-2230 represents a novel approach to neuropathic pain:
- Sodium channel (Nav1.7/1.8) blocker
- Potential for treatment-resistant pain conditions
Science and Technology
iPSC Technology
Sumitomo's cell therapy platform leverages induced pluripotent stem cell (iPSC) technology:
- Patient-derived or donor-derived iPSCs
- Directed differentiation to dopaminergic neuron progenitors
- GMP manufacturing for clinical use
- Potential for immune-matched cell therapy
TAAR1 Targeting
Trace amine-associated receptor 1 (TAAR1) is a novel target for psychiatric disorders:
- Expressed in brain regions involved in dopamine regulation
- May modulate monoamine neurotransmission
- Novel mechanism distinct from dopamine antagonists
Business Highlights
- Revenue (FY2024): Approximately $3.5 billion USD (500 billion JPY)
- R&D Investment: Approximately $800 million USD (120 billion JPY)
- Key Focus Areas: CNS, oncology, regenerative medicine
- Strategic Partnerships: Academic collaborations, biotech partnerships
- [Parkinson's Disease](/genes/ar)
- [Schizophrenia](/diseases/schizophrenia)
- [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
- [Cell Therapy](/therapeutics/cell-therapy)
- [iPSC Therapy](/genes/th)
- [Dopaminergic Neurons](/cell-types/dopaminergic-neurons)
- [Dopamine Signaling](/mechanisms/dopamine-signaling)
- [RNA Splicing](/mechanisms/rna-splicing)
- [TAAR1 Signaling](/genes/ar)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/genes/ar)
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
References
Sumitomo Pharma, Company Website (n.d.)
Corporate History, Sumitomo Pharma History (n.d.)
CTI-ND1601 Program, ClinicalTrials.gov (n.d.)
Neuroscience Pipeline, R&D Presentation (n.d.)
[iPSC Therapy for PD, Nature Reviews Drug Discovery (n.d.)](https://doi.org/10.1038/s41573-022-00463-9)
SEP-363856 Approval, PMDA Approval (n.d.)
[TAAR1 in Schizophrenia, Molecular Psychiatry (n.d.)](https://doi.org/10.1038/s41380-021-01079-0)